Lilly signs deal to sell $210M worth of COVID-19 antibodies to U.S. government
The Indianapolis-based drugmaker said it will begin shipping the additional doses immediately to the federal government, which controls distribution of the drugs.
Eli Lilly and Co.
Articles
Indiana Senate panel advances bill that would pass along drug rebates to consumers
The bill pitted the two largest companies headquartered in Indianapolis—drugmaker Eli Lilly and Co. and health insurer Anthem Inc.—on opposite sides of the issue.
Lilly’s flush pipeline makes it Wall Street darling
If you follow the daily drumbeat of news emanating out of Lilly Corporate Center, you might not grasp how phenomenally well the company is poised to perform in the coming years.
Former Lilly CFO Smiley to lose millions of dollars under separation agreement
Josh Smiley, Lilly’s CFO since 2018, resigned from the company after the drugmaker said he had engaged in a improper personal relationship with an employee.
Lilly’s COVID-19 antibody combo gets U.S. emergency authorization
The combo treatment is the second COVID-19 antibody therapy from the Indianapolis-based drugmaker to gain an emergency authorization from the FDA.
Lilly CFO resigns after ‘inappropriate personal relationship’ with employee
Joshua Smiley, who was Lilly’s second-highest-paid employee, was named CFO in January 2018. Lilly said Smiley also engaged in “inappropriate personal communications” with other employees.
Hope at Lilly after years of Alzheimer’s failures
Lilly has spent three decades and more than $3 billion trying to find a way to treat Alzheimer’s disease. Its latest drug, donanemab, finally shows real promise.
Lilly quarterly profit surges, helped by new COVID-19 treatment
The antibody treatment bamlanivimab was Lilly’s second-highest selling product in the final quarter of 2020, trailing only the popular diabetes drug Trulicity.
Eli Lilly, Glaxo join forces to test COVID-19 antibody cocktail
GlaxoSmithKline and partner Vir Biotechnology Inc. have teamed up with Indianapolis-based Eli Lilly and Co. to test a combination of their COVID-19 antibody treatments to see whether they can better combat the virus and its variants together.
Lilly to help Dutch biotech develop cancer therapies in deal worth up to $1.6B
Merus N.V. specializes is so-called CD3 engaging T-cell therapies, a growing area of cancer research, based on immunotherapy, or using the immune system’s T cells to find and shrink tumors
Lilly invests $30M in new fund for minority health-care startups
The Indianapolis-based drugmaker said people from minority communities are frequently “unseen” by the U.S. health care system.
Lilly suspends contributions to 4 Indiana Congress members over certification votes
Several other Indiana companies also say they are suspending contributions to all candidates or are taking a close look at the matter.
In midst of pandemic, drugmakers raise prices on hundreds of prescription drugs
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
Lilly shares surge after its potential Alzheimer’s drug slows cognitive decline
The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.
Lilly’s COVID treatment sparks little demand
For a highly touted drug meant to keep throngs of people out of hospitals during a pandemic, Eli Lilly and Co.’s wonder treatment bamlanivimab sure has been slow to catch on.
Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom
Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from the drugs made by Eli Lilly and Co. and Regeneron Pharmaceuticals.
Eli Lilly shares rise on Prevail acquisition, optimistic forecast
Lilly stock climbed Tuesday after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment.
Study: Drug combo with Lilly medication boosts COVID recovery time
Doctors are reporting that a two-drug treatment involving a medication from Indianapolis-based Eli Lilly and Co. is especially helpful for COVID-19 patients who need extra oxygen.
CVS to give Eli Lilly therapy to COVID-19 patients at home
The medication will be provided by the U.S. government, which paid Indianapolis-based Lilly $375 million for an initial two-month supply of 300,000 doses as part of the Operation Warp Speed program.
Lilly starting new trial for COVID-19 antibody, potentially widening already red-hot market
Lilly said it will enroll up to 500,000 people in its latest study, with at least 5,000 people expected to receive bamlanivimab therapy. The drugmaker is partnering with health insurer UnitedHealth Group to see if the drug will help high-risk people.